Apellis Pharmaceuticals, Inc. – NASDAQ:APLS
Founder-led company
Apellis Pharmaceuticals stock price today
$26.62
-6.05
-18.54%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Apellis Pharmaceuticals stock price monthly change
-17.33%
month
Apellis Pharmaceuticals stock price quarterly change
-17.33%
quarter
Apellis Pharmaceuticals stock price yearly change
-48.08%
year
Apellis Pharmaceuticals key metrics
Market Cap | 4.09B |
Enterprise value | 8.25B |
P/E | -12.72 |
EV/Sales | 109.42 |
EV/EBITDA | -13.36 |
Price/Sales | 115.24 |
Price/Book | 51.16 |
PEG ratio | -0.41 |
EPS | -3.46 |
Revenue | 512.85M |
EBITDA | -408.47M |
Income | -417.27M |
Revenue Q/Q | 284.25% |
Revenue Y/Y | 384.33% |
Profit margin | -864.7% |
Oper. margin | -788.38% |
Gross margin | 92.53% |
EBIT margin | -788.38% |
EBITDA margin | -79.65% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeApellis Pharmaceuticals stock price history
Apellis Pharmaceuticals stock forecast
Apellis Pharmaceuticals financial statements
Average Price Target
$62.8
Potential upside: 135.91%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 94.96M | -122.03M | -128.5% |
|---|---|---|---|
| Sep 2023 | 99.18M | -140.23M | -141.39% |
| Dec 2023 | 146.37M | -88.57M | -60.51% |
| Mar 2024 | 172.32M | -66.42M | -38.55% |
| Jun 2023 | 915578000 | 570.17M | 62.27% |
|---|---|---|---|
| Sep 2023 | 818216000 | 585.94M | 71.61% |
| Dec 2023 | 788730000 | 594.20M | 75.34% |
| Mar 2024 | 831930000 | 565.25M | 67.94% |
| Jun 2023 | -150.15M | -372K | 1.56M |
|---|---|---|---|
| Sep 2023 | -169.08M | -47K | 5.74M |
| Dec 2023 | -97.87M | 4K | -3.91M |
| Mar 2024 | -132.98M | -293K | 108.21M |
Apellis Pharmaceuticals alternative data
| Sep 2023 | 767 |
|---|---|
| Oct 2023 | 767 |
| Nov 2023 | 767 |
| Dec 2023 | 767 |
| Jan 2024 | 767 |
| Feb 2024 | 767 |
| Mar 2024 | 702 |
| Apr 2024 | 702 |
| May 2024 | 702 |
| Jun 2024 | 702 |
| Jul 2024 | 702 |
Apellis Pharmaceuticals other data
100.00%
+7.52%
of APLS is owned by hedge funds
225
+21
91.57M
+882.21K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 83485 |
| Feb 2024 | 0 | 9067 |
| Mar 2024 | 0 | 365105 |
| Apr 2024 | 0 | 73107 |
| May 2024 | 0 | 78907 |
| Jun 2024 | 0 | 37000 |
| Sep 2024 | 0 | 37742 |
| Dec 2024 | 0 | 5063 |
| Patent |
|---|
Application Filling date: 17 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 21 Sep 2021 Issue date: 11 Aug 2022 |
Application Filling date: 2 Jul 2020 Issue date: 11 Aug 2022 |
Grant Filling date: 18 Dec 2020 Issue date: 9 Aug 2022 |
Grant Filling date: 16 Oct 2017 Issue date: 24 May 2022 |
Grant Utility: Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods Filling date: 25 Jun 2020 Issue date: 5 Apr 2022 |
Grant Utility: Detection of high risk drusen Filling date: 3 Apr 2020 Issue date: 5 Apr 2022 |
Application Filling date: 22 Jun 2021 Issue date: 24 Mar 2022 |
Application Filling date: 20 Apr 2021 Issue date: 10 Feb 2022 |
Application Filling date: 29 Apr 2021 Issue date: 30 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 31 Jul 2023 | Q2 2023 Earnings Call Transcript |
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
Apellis Pharmaceuticals: Have Some Patience
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
A Second Look At Lineage Cell Therapeutics
Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade)
Apellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition Space
Apellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric Bio
Apellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy Market
-
What's the price of Apellis Pharmaceuticals stock today?
One share of Apellis Pharmaceuticals stock can currently be purchased for approximately $26.62.
-
When is Apellis Pharmaceuticals's next earnings date?
Unfortunately, Apellis Pharmaceuticals's (APLS) next earnings date is currently unknown.
-
Does Apellis Pharmaceuticals pay dividends?
No, Apellis Pharmaceuticals does not pay dividends.
-
How much money does Apellis Pharmaceuticals make?
Apellis Pharmaceuticals has a market capitalization of 4.09B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 425.83% to 396.59M US dollars.
-
What is Apellis Pharmaceuticals's stock symbol?
Apellis Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "APLS".
-
What is Apellis Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Apellis Pharmaceuticals?
Shares of Apellis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Apellis Pharmaceuticals's key executives?
Apellis Pharmaceuticals's management team includes the following people:
- Dr. Cedric Francois Co-Founder, Pres, Chief Executive Officer & Director(age: 53, pay: $1,050,000)
- Mr. Timothy E. Sullivan Chief Financial Officer(age: 54, pay: $687,960)
- Dr. Pascal Deschatelets Ph.D. Co-Founder & Chief Scientific Officer(age: 55, pay: $674,360)
- Mr. Adam J. Townsend Chief Commercial Officer(age: 48, pay: $657,290)
- Mr. Alec Machiels J.D., MBA Co-Founder & Independent Director(age: 52, pay: $67,500)
-
Is Apellis Pharmaceuticals founder-led company?
Yes, Apellis Pharmaceuticals is a company led by its founders Dr. Cedric Francois, Dr. Pascal Deschatelets Ph.D. and Mr. Alec Machiels J.D., MBA.
-
How many employees does Apellis Pharmaceuticals have?
As Jul 2024, Apellis Pharmaceuticals employs 702 workers.
-
When Apellis Pharmaceuticals went public?
Apellis Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 9 Nov 2017.
-
What is Apellis Pharmaceuticals's official website?
The official website for Apellis Pharmaceuticals is apellis.com.
-
Where are Apellis Pharmaceuticals's headquarters?
Apellis Pharmaceuticals is headquartered at 100 Fifth Avenue, Waltham, MA.
-
How can i contact Apellis Pharmaceuticals?
Apellis Pharmaceuticals's mailing address is 100 Fifth Avenue, Waltham, MA and company can be reached via phone at +61 79775700.
-
What is Apellis Pharmaceuticals stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Apellis Pharmaceuticals in the last 12 months, the avarage price target is $62.8. The average price target represents a 135.91% change from the last price of $26.62.
Apellis Pharmaceuticals company profile:
Apellis Pharmaceuticals, Inc.
apellis.comExchange:
NASDAQ
Full time employees:
702
Industry:
Biotechnology
Sector:
Healthcare
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
100 Fifth Avenue
Waltham, MA 02451
Waltham, MA 02451
CIK: 0001492422
ISIN: US03753U1060
CUSIP: 03753U106
